Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $89.9 million.

  • Axsome Therapeutics' Other Non-Current Liabilities rose 830.32% to $89.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year increase of 830.32%. This contributed to the annual value of $91.7 million for FY2024, which is 2507.5% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Other Non-Current Liabilities is $89.9 million, which was up 830.32% from $79.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Other Non-Current Liabilities ranged from a high of $91.7 million in Q4 2024 and a low of $27.4 million during Q3 2022
  • Moreover, its 4-year median value for Other Non-Current Liabilities was $69.8 million (2024), whereas its average is $59.3 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 16301.11% in 2024, then soared by 830.32% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Other Non-Current Liabilities (Quarter) stood at $31.1 million in 2022, then surged by 135.69% to $73.3 million in 2023, then increased by 25.08% to $91.7 million in 2024, then decreased by 1.97% to $89.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $89.9 million for Q3 2025, versus $79.7 million for Q2 2025 and $90.6 million for Q1 2025.